{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:11:08Z","timestamp":1778940668711,"version":"3.51.4"},"reference-count":42,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Gilead Sciences, Inc.","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Patient Care and STDs"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:p>Lenacapavir (LEN), a twice-yearly injectable long-acting capsid inhibitor used in combination with an optimized background regimen, is indicated for heavily treatment-experienced adults with multi-drug-resistant HIV-1 infection. From the US Observational Pharmaco-Epidemiology Research &amp; Analysis (OPERA) cohort, 116 adults with HIV with \u22651 set of LEN injections were included [baseline viral load (VL) &lt;200 copies\/mL = 74; \u2265200 copies\/mL = 42]. Many (56%) simplified their regimen at LEN initiation and\/or later, and 31% maintained all the antiretrovirals (ARVs) from their prior regimen throughout LEN use. Among those with a baseline VL &lt;200 copies\/mL, the cumulative probability (Kaplan\u2013Meier) of maintaining suppression to &lt;200 copies\/mL was 92% [95% confidence interval (CI): 80, 96]. Among those with a baseline VL \u2265200 copies\/mL, the cumulative probability of achieving suppression was 73% (95% CI: 59, 86). Among 78 individuals who received \u22652 sets of LEN injections, 82% received all sets of injections on time or early (\u226428 weeks after the prior set) and 18% received \u22651 set late (&gt;28 weeks after the prior set). The median delay was 11 days past the injection window (interquartile range: 4, 118). At study end, 91% remained on a LEN-containing regimen. In this cohort representative of routine clinical care in the United States, factors other than virologic control may be driving the decision to start LEN (e.g., safety, tolerability, resistance, simplification). Most people experienced favorable virologic outcomes and good adherence to LEN, which may serve as an effective option for those who could benefit from a long-acting injectable agent from a novel ARV class.<\/jats:p>","DOI":"10.1177\/10872914261437163","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T10:22:13Z","timestamp":1774693333000},"page":"186-194","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Lenacapavir-Containing Antiretroviral Therapy in the OPERA Cohort: Patterns of Use and Treatment Outcomes"],"prefix":"10.1177","volume":"40","author":[{"given":"Karam","family":"Mounzer","sequence":"first","affiliation":[{"name":"Philadelphia FIGHT, Philadelphia, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-4835","authenticated-orcid":false,"given":"Laurence","family":"Brunet","sequence":"additional","affiliation":[{"name":"Epividian, Inc., Raleigh, North Carolina, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricky K.","family":"Hsu","sequence":"additional","affiliation":[{"name":"AIDS Healthcare Foundation, NYU Langone Medical Center, New York, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip C.","family":"Lackey","sequence":"additional","affiliation":[{"name":"School of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Sension","sequence":"additional","affiliation":[{"name":"CAN Community Health, Fort Lauderdale, Florida, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Wohlfeiler","sequence":"additional","affiliation":[{"name":"AIDS Healthcare Foundation, Miami, Florida, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Dunn","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S.","family":"Fusco","sequence":"additional","affiliation":[{"name":"Epividian, Inc., Raleigh, North Carolina, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory P.","family":"Fusco","sequence":"additional","affiliation":[{"name":"Epividian, Inc., Raleigh, North Carolina, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit529"},{"key":"e_1_3_3_3_1","volume-title":"ART Failure and Strategies for Switching ART Regimens in the WHO European region","author":"WHO Expert Consultation","year":"2007","unstructured":"2.WHO Expert Consultation. ART Failure and Strategies for Switching ART Regimens in the WHO European region. WHO: Copenhagen; 2007."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2006.0310"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2012.712667"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/11633630-000000000-00000"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq243"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(06)70550-3"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/2049936120901395"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm522"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000174455.01369.ad"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00650.x"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200005050-00004"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3281532ca7"},{"key":"e_1_3_3_15_1","unstructured":"14.Pelchen-Matthews A Borges A Reekie J et al. Prevalence and Outcomes for Heavily Treatment-Experienced (HTE) Individuals Living with HIV in a European Cohort. International AIDS Society (IAS) Conference on HIV Science. Mexico City Mexico. 2019."},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182618f05"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(04)16589-6"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab562"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08038-w"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035026"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000185314.56556.c3"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902493"},{"issue":"3","key":"e_1_3_3_23_1","first-page":"180","article-title":"Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: From clinical trials to daily clinical practice","volume":"13","author":"Imaz A","year":"2011","unstructured":"22.Imaz A, , Falco V, , Ribera E. Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: From clinical trials to daily clinical practice. AIDS Rev 2011;13(3):180\u2013193.","journal-title":"AIDS Rev"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(06)69154-x"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.3.5.815"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S192735"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2018.1469725"},{"key":"e_1_3_3_28_1","unstructured":"27.U.S. Food & Drug Administration. FDA Approves New HIV Drug for Adults with Limited Treatment Options\u2014Sunlenca. 2022. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-hiv-drug-adults-limited-treatment-options [Last accessed: February15 2023]."},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb4808"},{"key":"e_1_3_3_30_1","unstructured":"29.Gilead Sciences. SUNLENCA Prescribing Information. 2022."},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115542"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.108"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00113-3"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae423"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.041"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.12.011"},{"key":"e_1_3_3_37_1","unstructured":"36.Delaugerre C Mafi S Zenuni A et al. EP0195. Capsid inhibition with lenacapavir in HIV-1 infection: Real-life results from the French Compassionate Use Program. 13th International AIDS Society Conference on HIV Science (IAS). Kigali Rwanda; 2025."},{"key":"e_1_3_3_38_1","unstructured":"37.Palich R Ghosn J Valantin M-A et al. eP101\u2014Real world use of lenacapavir in France: A national observational study. 20th European AIDS Conference. Paris France; 2025."},{"key":"e_1_3_3_39_1","volume-title":"20th European AIDS Conference","author":"Charpentier C","year":"2025","unstructured":"38.Charpentier C, , Montrouge T, , Wirden M, et al. A French national real-world observatory of people initiating a lenacapavir-based treatment during the post-approval period. 20th European AIDS Conference. Paris, France; 2025."},{"issue":"1","key":"e_1_3_3_40_1","article-title":"Virologic outcomes with lenacapavir in heavily treatment-experienced people with HIV: A multi-center real-world study","volume":"13","author":"Kaperak C","year":"2025","unstructured":"39.Kaperak C, , Li Y, , Guevara FS, et al. Virologic outcomes with lenacapavir in heavily treatment-experienced people with HIV: A multi-center real-world study. Open Forum Infect Dis 2025;13(Suppl 1).","journal-title":"Open Forum Infect Dis"},{"key":"e_1_3_3_41_1","unstructured":"40.Torkjazi G Galli L Gagliardini R et al. Efficacy and durability of fostemsavir ibalizumab or lenacapavir-including regimens in people living with multidrug-resistant HIV-1: Results from the PRESTIGIO registry [ePOSTER P.B1.031]. 19th European AIDS Conference (EACS). Warsaw Poland; 2023."},{"key":"e_1_3_3_42_1","unstructured":"41.Shaik NA Bellanti F Comisar C et al. Population-PK analysis to guide dosing window following lenacapavir SC administration. Conference on Retroviruses and Opportunistic Infections (CROI). Seattle WA USA; 2023."},{"key":"e_1_3_3_43_1","unstructured":"42.Centers for Disease Control and Prevention. Diagnoses deaths and prevalence of HIV in the United States and 6 territories and freely associated states 2022. HIV Surveillance Report 2022; vol. 35. 2024. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/156509 [Last accessed: June26 2024]."}],"container-title":["AIDS Patient Care and STDs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10872914261437163","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10872914261437163","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10872914261437163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:47:40Z","timestamp":1778939260000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10872914261437163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"alternative-id":["10.1177\/10872914261437163"],"URL":"https:\/\/doi.org\/10.1177\/10872914261437163","relation":{},"ISSN":["1087-2914","1557-7449"],"issn-type":[{"value":"1087-2914","type":"print"},{"value":"1557-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]}}}